– USA, CA – DIMERx, a leading pioneer of covalent chemistry-based dimer technology, today announced the appointment of Peter Barton Hutt and Harvinder Dhani to its Board of Directors.
About Peter Barton Hutt
Peter Barton Hutt brings with him a wealth of complex regulatory and pharmaceutical experience amassed over career-spanning decades. He is a senior counsel in the Washington, DC law firm of Covington & Burling LLP. Except for his 4 years in the government, Mr. Hutt has continued at the firm for most of his career. As the chief counsel at the FDA during 1971-1975, he transformed the Agency from outdated law enforcement to modern administrative law. Outside the government, he drafted the legislation that led to the creation of the National Institute of Alcohol Abuse and Addiction and the National Institute of Drug Addiction. He continues to serve on a wide variety of other academic and scientific Advisory Boards, on the Board of Directors of venture capital startup companies, and on the Advisory Boards of venture capital firms.
About Harvinder Dhani
Harvinder Dhani brings a wealth of expertise as a seasoned health tech investor with a deep commitment to societal altruism that aligns perfectly with DIMERx’s mission to improve healthcare outcomes. Mr. Dhani’s distinguished career in the healthcare technology sector spans over two decades, during which he has demonstrated an unwavering dedication to advancing healthcare solutions that benefit not only patients but also society as a whole. His vision for ethical, patient-centric healthcare innovation and his track record of successful investments make him a valuable resource to the DIMERx leadership team.
About DIMERx, Inc.
DIMERx is a clinical-stage biopharmaceutical company focused on the development of innovative and de-risked first-in-class dimer therapeutics. Leveraging its proprietary dimer platform technology engineered by founder Nikhilesh Singh, Ph.D., DIMERx is advancing DMX-101 and a pipeline of additional dimer conjugates. DIMERx is currently raising Series A financing to see DMX-101 through clinical proof of concept for chronic pain and advance at least one additional dimer to the point of filing an Investigational New Drug submission with the FDA. DMX-101 is also Phase 2b/3a ready for chronic treatment of IBS-D in patients with and without gallbladder.
For more information: https://www.dimerx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.